MENU

SLS Stock Tickeron detected bullish Stock Pattern: Cup-and-Handle SLS on April 15, 2025, netting in a 9.32% gain over 3 weeks

A.I.dvisor
at Tickeron.com
Loading...
+9.32% Gain from a Successful pattern Cup-and-Handle
SLS - SELLAS Life Sciences Group
Tickeron
Ticker: SLS
Company: SELLAS Life Sciences Group
Gain: +9.32%
Confirmed: 04/15/25
Succeeded: 04/22/25
Total length: 27 days
On March 26, 2025, A.I.dvisor detected a Cup-and-Handle Pattern (Bullish) for SELLAS Life Sciences Group (SLS, $1.18). On April 15, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $1.38. 7 days later, on April 22, 2025, SLS reached the target price resulting in a for traders who took a long position in the stock.

Momentum Indicator for SLS turns positive, indicating new upward trend

SLS saw its Momentum Indicator move above the 0 level on April 11, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SLS just turned positive on April 11, 2025. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

SLS moved above its 50-day moving average on April 15, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SLS crossed bullishly above the 50-day moving average on April 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for SLS moved above the 200-day moving average on March 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SLS broke above its upper Bollinger Band on April 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SLS entered a downward trend on March 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.531) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
16
Web
https://www.sellaslifesciences.com